These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 3408634)

  • 1. Concentration-effect relationships for oxprenolol in patients with essential hypertension.
    McInnes GT; Brodie MJ
    Br J Clin Pharmacol; 1988 May; 25(5):539-45. PubMed ID: 3408634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension.
    McInnes GT; Brodie MJ
    Eur J Clin Pharmacol; 1988; 34(6):605-11. PubMed ID: 3169112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exercise and resting blood pressure and heart rate changes 24 h after dosing in patients with essential hypertension receiving 16/260 oxprenolol Oros once daily.
    Müller FB; Allsopp LF; Cooper GL; Bolli P; Frei P; Glaus L; Ritz R; Bühler FR
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):207S-212S. PubMed ID: 4005124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-dosing plasma concentrations and beta-adrenoceptor blocking effects during repeated once daily dosing with 160 mg sustained-release propranolol (Inderal LA) and 16/260 oxprenolol Oros to healthy volunteers.
    Moppert J; Degen PH; Racine-Poon A
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):197S-201S. PubMed ID: 2988591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of single doses of bucindolol and oxprenolol in hypertensive patients.
    Webster J; Petrie JC; Robb OJ; Jamieson M; Verschueren J
    Br J Clin Pharmacol; 1985 Oct; 20(4):393-400. PubMed ID: 2866786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer-matrix and Oros dosage forms of oxprenolol in healthy volunteers.
    Woods KL; Jack DB; Kendall MJ; Halsey A; O'Donnell ML; Warrington SJ; John VA
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):177S-184S. PubMed ID: 4005120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twenty-four hour effects of oxprenolol Oros and atenolol on heart rate, blood pressure, exercise tolerance and perceived exertion.
    van Baak MA; Verstappen FT; Oosterhuis B
    Eur J Clin Pharmacol; 1986; 30(4):399-406. PubMed ID: 3743615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose pharmacokinetic and pharmacodynamic comparison of polymer-matrix (Slow Trasicor) and Oros dosage forms of oxprenolol in healthy volunteers.
    Bennett PN; Bennett J; Bradbrook I; Francis J; John VA; Rogers H; Turner P; Warrington SJ
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):171S-175S. PubMed ID: 4005119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of slow release oxprenolol with conventional oxprenolol in the treatment of hypertension.
    Resnekov EB; Havard CW
    Eur J Clin Pharmacol; 1978 Nov; 14(2):77-81. PubMed ID: 363434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the effects of the slow release formulations of metoprolol and oxprenolol in hypertension.
    Comerford MB; Besterman EM
    Ann Clin Res; 1982 Feb; 14(1):27-31. PubMed ID: 7137874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of pharmacokinetic profiles of single and multiple doses of a slow release Oros oxprenolol delivery system in young normotensive and elderly hypertensive subjects.
    Bradbrook ID; Babiker M; Crome P; Gillies HC; Morrison PJ; Rogers HJ; Shotton P
    Br J Clin Pharmacol; 1986 Apr; 21(4):371-6. PubMed ID: 3707811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of oxprenolol slow release and osmotic release by exercise testing and ambulatory electrocardiographic monitoring in patients with chronic stable angina pectoris.
    Bowles MJ; Khurmi NS; O'Hara MJ; Raftery EB
    Eur J Clin Pharmacol; 1987; 32(2):127-33. PubMed ID: 3556193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic modelling of oxprenolol in man using continuous non-invasive blood pressure monitoring.
    Koopmans R; Oosterhuis B; Karemaker JM; Wemer J; van Boxtel CJ
    Eur J Clin Pharmacol; 1988; 34(4):395-400. PubMed ID: 3402525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproducibility of oxprenolol plasma concentrations in young female volunteers following oral administration of an oxprenolol Oros dosage form.
    Jack DB; Kendall MJ; Laugher SJ; Smith SR
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):185S-190S. PubMed ID: 4005121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial of combination of guanethidine and oxprenolol in hypertension.
    Pearson RM; Bending MR; Bulpitt CJ; George CF; Hole DR; Williams FM; Breckenridge AM
    Br Med J; 1976 Apr; 1(6015):933-6. PubMed ID: 773486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of food intake on plasma oxprenolol concentrations following oral administration of conventional and Oros preparations.
    John VA; Smith SE
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):191S-195S. PubMed ID: 4005122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics of oxprenolol following oral and rectal dosing--a comparison of delivery systems and routes of administration.
    Gregg MR; Jack DB; Smith SR; Kendall MJ
    J Clin Pharm Ther; 1987 Apr; 12(2):91-9. PubMed ID: 3584272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of oxprenolol dosage time on its pharmacokinetics and haemodynamic effects during exercise in man.
    Koopmans R; Oosterhuis B; Karemaker JM; Wemer J; van Boxtel CJ
    Eur J Clin Pharmacol; 1993; 44(2):171-6. PubMed ID: 8453962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of oxprenolol on the intra-arterial blood pressure response to dynamic exercise in hypertensive men.
    Millar-Craig MW; Mann S; Balasubramanian V; Cashman P; Raftery EB
    J Cardiovasc Pharmacol; 1981; 3(3):468-76. PubMed ID: 6168828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Continuous 24-hour registration of intra-arterial pressure in basal states and during therapy with a fixed slow-release oxprenolol-chlorthalidone combination, administered once a day].
    Fariello R; Alicandri C; Boni E; Montini E; Zaninelli A; Agabiti-Rosei E; Motolese M; Muiesan G
    G Ital Cardiol; 1984 Feb; 14(2):121-6. PubMed ID: 6714549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.